A New Candidate Supporting Drug, Rikkunshito, for the QOL in Advanced Esophageal Cancer Patients with Chemotherapy Using Docetaxel/5-FU/CDDP

Autor: Junichi Seike, Toru Sawada, Naoya Kawakita, Yota Yamamoto, Yasuhiro Yuasa, Hiromichi Yamai, Hirokazu Takachi, Takahiro Yoshida, Akira Tangoku
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Zdroj: International Journal of Surgical Oncology, Vol 2011 (2011)
Druh dokumentu: article
ISSN: 2090-1402
2090-1410
DOI: 10.1155/2011/715623
Popis: Purpose. Docetaxel/5-FU/CDDP (DFP) therapy is a useful treatment for advanced esophageal cancer. However, adverse reactions such as chemotherapy-induced nausea and vomiting (CINV) interfere often with continuation of the chemotherapy. We investigated the efficacy of rikkunshito (TJ-43) on CINV. Methods. Nineteen patients who were going to undergo DFP therapy were enrolled. They were assigned to the following two groups: a TJ-43-treated group and -nontreated group. The following parameters were compared between the 2 groups: (1) the frequency of symptoms occurred, (2) vomiting, nausea, and anorexia score, and (3) QOL score. Results. The incidence of symptoms was lower in the TJ-43-treated group than that in the control group. The nausea score of the TJ-43-treated group was significantly lower than that of the control group. In the QOL score, the mood score and the ADL score decreased significantly in the control group. Conclusion. We recommend TJ-43 administration in patients undergoing DFP chemotherapy.
Databáze: Directory of Open Access Journals
Externí odkaz: